Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-212 in Advanced Malignancies
NCT05707325Phase 1Recruiting
- Sponsor
- Westlake Therapeutics
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of WTX212A in malignant neoplasms (advanced stage), solid tumor and hematologic malignancy (2 arms), sponsored by Westlake Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 24 months. Started Jan 2023; status: recruiting.
02
Drugs
WTX212A
03
Conditions
malignant neoplasms (advanced stage)solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT05707325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707325.